Aurora Reports 20% YoY Uptick In Global Medical Marijuana, Expects Benefits From International Cannabis Regulatory Reforms
Aurora Reports 20% YoY Uptick In Global Medical Marijuana, Expects Benefits From International Cannabis Regulatory Reforms
大麻股在全球医疗大麻市场出现20%的年增长，预计将受益于国际大麻监管改革。
Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB) announced its financial and operational results Thursday for the fourth quarter and fiscal year 2024.
奥罗拉大麻公司（纳斯达克股票代码：ACB）（多伦多证券交易所股票代码：ACB）周四公布了第四季度和2024财年的财务和经营业绩。
The Alberta-based cannabis giant noted the year-over-year comparison quarter for the fourth quarter of 2024 ending March 31, 2024, is the third quarter of fiscal 2023 ending March 31, 2023, as the fiscal year 2023 consisted of three quarters.
这家总部位于艾伯塔省的大麻巨头指出，截至2024年3月31日的2024年第四季度的同比比较季度是截至2023年3月31日的2023财年第三季度，因为2023财年由三个季度组成。
The company reported a 5% year-over-year increase in revenue to CA$67.4 million ($49.1 million) in the fourth quarter.
该公司报告称，第四季度收入同比增长5％，达到6,740万加元（合4,910万美元）。
Global medical cannabis net revenue grew by 20% over the same period to CA$45.6 million. The increase in net revenue1 of $7.7 million was primarily due to higher sales...
全球医用大麻净收入同期增长了20％，达到4560万加...
登录免费看全文
登录/注册